14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ASND
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Monday for Ascendis Pharma A/S
(Updated on May 06, 2024)

Sell candidate since May 03, 2024 Loss -2.33% PDF

The Ascendis Pharma A/S stock price fell by -2.33% on the last day (Monday, 6th May 2024) from $137.20 to $134.00. During the last trading day the stock fluctuated 3.62% from a day low at $133.53 to a day high of $138.36. The price has fallen in 6 of the last 10 days and is down by -5.7% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -73 thousand shares and in total, 438 thousand shares were bought and sold for approximately $58.72 million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -6.17% during the next 3 months and, with a 90% probability hold a price between $121.36 and $141.91 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ASND Signals & Forecast

There are few to no technical positive signals at the moment. The Ascendis Pharma A/S stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $138.26 and $144.69. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, February 23, 2024, and so far it has fallen -15.93%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Ascendis Pharma A/S stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $4.83 between high and low, or 3.62%. For the last week, the stock has had daily average volatility of 4.08%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ASND) For The Upcoming Trading Day Of Tuesday 7th

For the upcoming trading day on Tuesday, 7th we expect Ascendis Pharma A/S to open at $135.30, and during the day (based on 14 day Average True Range), to move between $128.61 and $139.39, which gives a possible trading interval of +/-$5.39 (+/-4.02%) up or down from last closing price. If Ascendis Pharma A/S takes out the full calculated possible swing range there will be an estimated 8.04% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $139.29, some $5.29 (3.95%) from the current price of $134.00, our system finds the risk reward not very attractive.

Is Ascendis Pharma A/S stock A Buy?

Ascendis Pharma A/S holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.552 Sell Candidate Unchanged

Predicted Opening Price for Ascendis Pharma A/S of Tuesday, May 7, 2024

Fair opening price May 7, 2024 Current price
$135.30 ( 0.97%) $134.00

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ASND

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 140.13 4.57 %
R2 138.28 3.20 %
R1 137.14 2.34 %
Current price: 134.00
Support S1 133.45 -0.409 %
S2 132.31 -1.26 %
S3 130.47 -2.64 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 145.37 8.49 %
R2 143.35 6.98 %
R1 139.29 3.95 %
Current price 134.00
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for Ascendis Pharma A/S Stock and on which exchange is it traded?
The symbol for Ascendis Pharma A/S is ASND and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Ascendis Pharma A/S Stock?
Ascendis Pharma A/S holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Ascendis Pharma A/S Stock?
Ascendis Pharma A/S Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Ascendis Pharma A/S Stock.

What's the current price of Ascendis Pharma A/S Stock?
As of the end of day on the May 06, 2024, the price of an Ascendis Pharma A/S (ASND) share was $134.00.

What is the 52-week high and low for Ascendis Pharma A/S Stock?
The 52-week high for Ascendis Pharma A/S Stock is $10.90 and the 52-week low is $0.400.

What is the market capitalization of Ascendis Pharma A/S Stock?
As of the May 06, 2024, the market capitalization of Ascendis Pharma A/S is 7.586B.

When is the next earnings date for Ascendis Pharma A/S?
The upcoming earnings date for Ascendis Pharma A/S is Sep 03, 2024.
Click to get the best stock tips daily for free!

About Ascendis Pharma A/S

Ascendis Pharma A/S Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra... ASND Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT